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Abstract AH-7921 is a structurally unique synthetic
opioid analgesic that has recently entered the drug arena in
Europe, the USA, and Japan. Although it was synthesized
and patented in the mid-1970s, it was first identified in a
seized sample purchased via the Internet in July 2012 and
formally brought to the attention of the European Union
early warning system in August 2012 by the United
Kingdom. Several in vitro experiments and animal model
studies established the morphine-like analgesic action of
AH-7921 as a l-opioid receptor agonist that has been
found to be several times more potent than codeine and at
least as potent as morphine. This novel psychoactive sub-
stance has already led to eight non-fatal intoxications and
16 deaths in Sweden, the United Kingdom, Norway, and
the USA. Thus, AH-7921 is a current public health risk,
and better international collaboration, effective legislation
and continuous community alertness are needed to tackle
this current growing problem. The aim of this review is to
summarize the current knowledge about this drug con-
cerning its chemistry, pharmacology, and toxicology, as
well as its international legal status. The limited existing
analytical methodologies for the determination of AH-7921
in biological samples are also presented. Published or
reported AH-7921-related cases, fatalities, or intoxications,
and self reports from drug users are reviewed.
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Introduction
New psychoactive substances (NPSs) are continuously
emerging on the recreational and illicit drug market. They
are often referred to as ‘‘legal highs’’, ‘‘designer drugs’’, or
‘‘bath salts’’ [1–3]. They are mainly synthetic derivatives
and analogues of existing controlled drugs, analogues of
pharmaceutical products, herbs, fungi, and their extracts
that show psychoactive actions. Some NPSs are controlled,
while others are legally sourced and can either be sold
directly on the drug market or be used as precursors for the
synthesis of other designer drugs that mimic the psy-
choactive effects of controlled substances [4, 5]; thus, due
to the chemical alterations of the parent compounds, NPS
derivatives can avoid drug legislation. Furthermore, for
most NPSs, pharmacological and analytical data are lim-
ited or unavailable, which makes detection, monitoring,
and control more difficult.
AH-7921 is a new, structurally atypical synthetic opioid
analgesic that appears to be sold as a ‘‘research chemical’’
or ‘‘legal opioid’’ on the Internet since 2012. It was syn-
thesized in the 1970s by Allen and Hanburys Ltd. as a
potential analgesic medicine; however, its development
was abandoned due to its addictive properties. It has never
been marketed as a medicine, nor used as pharmaceutical
or medicinal product; it has also no industrial use [6].
There are very few references available on this compound
[7]. In vivo studies in animals indicated its l-opioid
receptor agonistic activities, although no studies have
evaluated its pharmacological and toxicological properties
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in humans. Its activities are similar to those of morphine
and include analgesia, hypothermia, respiratory depression,
and addictive behavior [7–9]. The abuse of AH-7921 has
been reported in eight member states of the European
Union as well as in Norway, leading to severe toxicity
(non-fatal) cases and 16 reported deaths within a limited
period of time (December 2012–September 2013). Thus,
AH-7921 is controlled in six European countries (Sweden,
Poland, Romania, Finland, Netherlands, and Norway) since
2013 [6].
The aim of this review is to summarize the current
knowledge about AH-7921 concerning its chemistry,
pharmacology, and toxicology, as well as its legal status.
The limited existing analytical methodologies for deter-
mination of AH-7921 in biological samples are also pre-
sented. Published or reported AH-7921-related cases,
fatalities, intoxications, and self reports from drug users are
reviewed.
Chemistry
AH-7921 is an N-substituted cyclohexylmethylbenzamide,
where the benzamide moiety is dichlorinated at positions 3
and 4 of the benzyl ring, and the aminocyclohexane moiety
is N,N-dimethylated. ‘‘AH’’ refers to ‘‘Allen and Han-
burys’’, the company that patented the drug. Its systematic
(International Union of Pure and Applied Chemistry) name
is 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}
benzamide, but it can also be found as 1-(3,4-dichlor-
obenzamidomethyl)cyclohexyldimethylamine [6, 10].
Common names like doxylam, doxylan, and CN 2924 29
98 (CAS Number) are also used [6]. The chemical structure
of AH-7921 is shown in Fig. 1.
AH-7921 is an off-white solid with the molecular for-
mula C16H22Cl2N2O. Its molecular weight is 329.26 g/mol,
and the melting point of its hydrochloride salt is
215–216 C. It is soluble in ethanol (11 mg/ml), dime-
thylsulfoxide (3 mg/ml) and dimethylformamide (10 mg/
ml). The drug absorbs at 205 and 237 nm spectro-
photometrically [10].
Prevalence and use
AH-7921 appeared on the European drug market in 2012.
However, in July 2012 it was formally brought to the
attention of the European Union early warning system for
the first time by Norway and Sweden, and later, in August
2012, by the United Kingdom. In 2013, it was identified
as a co-ingredient in synthetic cannabinoid- and cath-
inone-derivative products sold in Japan [11]. AH-7921 is
sold via the Internet on various websites where it is
sometimes referred to as ‘‘doxylam’’, which is its alter-
native street name, and is also used in Internet drug
forums, ‘‘legal high’’ websites, and head shops. This name
may be confused with ‘‘doxylamine’’, the International
Nonproprietary Name of a widely used (non-prescription)
antihistaminic medicine with sedative-hypnotic properties
that is chemically completely different from AH-7921
(Fig. 1). Thus, intake of AH-7921 mislabeled as ‘‘dox-
ylamine’’ could lead to unintentional toxicity or overdoses
with the drug.
AH-7921 has no established or acknowledged industrial,
agrochemical, cosmetic, human, or veterinary medical
value or use, and thus there is neither marketing author-
ization for this NPS in the European Union nor in the 28
member states, Norway, and Iceland. AH-7921 is legiti-
mately used as an analytical reference standard and in
scientific research [6, 12, 13], and can be ordered online
from suppliers of chemicals. These licit products are, of
course, not intended for human consumption. Relative
labeling (‘‘analytical reference standard’’, ‘‘laboratory
reagent only’’, or ‘‘not for human consumption’’) appears
on some of the dubious products that are sold through the
Internet on different websites to conform to law [6].
According to the EMCDDA, AH-7921 collected from
street samples or drug seizures was in powder form;
however, it is not known whether the salt or free base forms
were present [6]. Internet licit retailers offer AH-7921 for
sale in the form of free base or as its hydrochloride salt
[12]. AH-7921 was first detected in the United Kingdom in
July 2012 in a collected sample of 250 mg of a white
powder purchased for 10 GBP via the Internet. Various
quantities of powder ranging from 0.02 (Sweden) to 500 g
(France) were seized between July 2012 and October 2013.
By March 2014, Europol received reports related to the
detection of AH-7921 in seized or collected materials at the
scene of death or in biological fluids from Austria, Bel-
gium, Denmark, Finland, France, Germany, Norway, and
Sweden [6, 14, 15].
Information about the dosage of AH-7921, the route of
administration, its purity when purchased (mainly online)
from drug retailers, and its concomitant use with other
substance(s), such as medicine(s) or alcohol, can be ex-
tracted from self-reported experiences in drug forums or
other related websites. The drug is consumed by nasal in-
sufflation, sublingual application, intravenous injection, a
combination of insufflation and oral consumption, or rectal
administration (in the form of powder, tablet, or capsule) at
doses ranging from 10 to 150 mg [10, 15–18]. An AH-
7921 user reports that ‘‘The threshold dose for me was
around 0.05 g. I explored doses up to 0.512 g. I also ex-
perimented with immediate tolerance using multiple doses.
I found that re-dosing between 1 a.m. and 3 a.m. produced
the smoothest increase in effects and duration’’ [17].
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Many users take AH-7921 in combination with other
psychoactive substances and/or controlled drugs, especially
cannabis [16, 17]. In some fatal or intoxication cases re-
ported by the member states and Norway, medicines,
controlled drugs, and/or other NPSs were also detected in
biological samples along with AH-7921 [14].
Pharmacology and toxicology
AH-7921 was designed, synthesized, developed, and
patented in the mid 1970s by researchers from the Uni-
versity of Aston (Birmingham) and the pharmaceutical
company Allen and Hanburys Ltd. It was synthesized
among other N-substituted cyclohexylmethylbenzamide
derivatives as a potential analgesic agent due to its struc-
tural similarity to fentanyl and phencyclidine (Fig. 1). AH-
7921 proved to be the most active compound of the
designed series in animal models tested possessing sig-
nificant analgesic properties (ED50 = 0.55 mg/kg). Espe-
cially in mouse, AH-7921 showed an analgesic action
equal to morphine (ED50 = 0.45 mg/kg) when inhibiting
phenylquinone-induced writhing [8]. After subcutaneous
administration in mice, the drug proved to be an
antinociceptive agent during hot-plate test [19].
Because early in vivo animal studies of AH-7921
revealed its potent analgesic activity, it was selected among
the series of N-substituted cyclohexylmethylbenzamides
for further investigation and detailed studies in higher
species. Particularly, orally administered doses of AH-7921
in conscious dogs led to suppression of pain response
(to electrical stimulation of the dental pulp) to an extent
similar to that of morphine with a minimal effective
antinociceptive oral dose of 1.25 mg/kg. The corre-
sponding analgesic dose for codeine was 3.5 mg/kg. In
rhesus monkeys, the minimal oral antinociceptive (for
similarly induced pain) doses of AH-7921, codeine, and
morphine were 13.8, 11.3, and B5.0 mg/kg, respectively.
These doses caused no overt behavioral effects in the
above examined animal models, although higher oral
doses of 50 mg/kg caused slight central nervous system
depression. Further studies by the same scientific group of
Allen and Hanburys Ltd. revealed the addictive liability
of AH-7921; administration of naloxone to rats that were
orally treated with 5 mg AH-7921/kg three times daily
that increased to 20 mg AH-7921/kg three times daily
over 5 days caused an withdrawal syndrome similar to
that produced in animals that had received morphine on a
similar dosage schedule. The symptoms were completely
alleviated after administration of certain doses of AH-
7921. In addition, on terminating AH-7921 treatment,
withdrawal signs appeared over a period of 24–48 h,
which indicates that the physical dependence produced is
similar to that of opioids [20].
Sewell and Spencer [21] in their study showed that the
antinociceptive effects of subcutaneously injected mor-
phine or AH-7921 were prolonged in both cases by intra-
cerebroventricularly injecting serotonin in mice, while
noradrenaline attenuated the antinociceptive effects of
these two analgesics. Thus, it was assumed that AH-7921
interacts in vivo with brain-penetrating serotonergic and
adrenergic drugs.
Fig. 1 Chemical structures of
AH-7921, fentanyl, doxylamine,
and phencyclidine
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More recent studies in rodents indicated that AH-7921
was a l-opioid receptor agonist, while j-opioid receptors
were also involved to its analgesic effect against chemi-
cally induced pain [19]. This moderate selectivity towards
l- over j-opioid receptors was also confirmed in vitro
using opioid receptor preparations from guinea pig brains
[22]. Hayes and Tyers [8] studied the antinociceptive
effects, as well as the adverse effects produced by AH-
7921 and other selected opioid receptor agonists, after
subcutaneous administration in mice. These adverse effects
included miosis, Straub tail response, hypothermia, seda-
tion, respiratory depression (ED50 = 2.5 mg/kg), and
inhibition of gastrointestinal propulsion. In general, these
effects of AH-7921 were similar to those of morphine,
indicating a shared mode of action at the receptor level,
while they were significantly reduced by simultaneous
subcutaneous administration of naloxone. These results
demonstrated that the doses that produced side effects were
close to those responsible for its analgesic action. In the
same study, morphine was found to have a twofold greater
safety margin than AH-7921, which suggests easier
appearance of toxic effects after AH-7921 use [8].
There are no published studies concerning the pharma-
cological or toxicological action of AH-7921 in humans
and the clinical features of its acute toxicity [7]. Most of
that information comes from drug users. Thus, the only
available information related to the use and the effects of
this drug is scarce and originates from Internet drug forums
and a limited number of recently published poisoning
cases. AH-7921 as a l-opioid receptor agonist produces
relaxation, euphoria, respiratory depression, nausea,
hypertension, and hypothermia, as users of this drug have
mentioned [6, 10]. However, it is difficult to estimate the
role of j-opioid receptor agonism in the overall physiolo-
gical and psychological effects of AH-7921 in humans.
Drug users reported that the desired (positive) effects of
AH-7921 after oral intake include physical anesthetic
effect, euphoria, mental relaxation, and pleasant mood lift,
while nausea and vertigo induced by movement appeared
as adverse (negative) effects that could be minimized by
having a meal 2–4 h prior to ingestion. According to a user
who had been in search of a substance that would provide
pain management and tried AH-7921 orally, ‘‘The effects
of AH-7921 seem to be highly predictable and repeatable.
Nearly every experience exhibited the same basic effects
on my mental and physical being. I found the intensity of
the effects to correspond in a linear relationship to the
dosage amount’’ [17].
An AH-7921 user mentioned that the inhalation of va-
pors in an amount of 40 mg as free base led to a very
relaxing and pleasant experience, euphoria, and pain relief
similar to those produced by doses of morphine as low as
10 mg. The peak-effects lasted for 1.5 h. No other effects
except warmness of body, extreme relaxation, analgesic
effects, medium euphoria, and miosis (occurring with the
use of other opioids) were noticed [16]. Two AH-7921
users experienced similar effects as well as an addition
‘‘opiate glow’’, alertness, occasional itching, nausea, and
tremors after sublingual administration and re-dosing of a
solution of powder AH-7921 in lemon juice and warm
water [23]. No serious adverse effects were observed by
these users.
A user who consumed orally in total 2 g of AH-7921 in
3 weeks experienced feelings of depression and mild
insomnia after withdrawal from the drug, while his second
experience resulted in a visit to hospital with ‘‘numbness,
spasms, and twitches’’ [18]. Other users have confirmed
that AH-7921 can lead to withdrawal symptoms worse than
morphine due to its much longer half-life [24].
Intoxication and fatal cases related to AH-7921 use
The growing recreational use of NPSs has led to an
increasing number of confirmed cases of severe intoxica-
tions and fatalities associated with their consumption in
Europe and worldwide [14]. According to the EMCDDA
report of 2014, the Swedish Poison Information Centre
reported eight non-fatal intoxications associated with AH-
7921 use between December 2012 and April 2013. The
presence of AH-7921 was analytically confirmed in seven
of these cases, but no information on AH-7921 quantifi-
cation was given. The clinical symptoms described in the
above cases included seizures, hypertension, and tachy-
cardia [6, 14, 15].
The first death associated with AH-7921 was reported
by Norway in December 2012. Since then, a total of 16
deaths in which AH-7921 was detected have been reported
from Sweden, the United Kingdom, and Norway [6, 14,
15].
Three fatal cases, in which the use of AH-7921 was
involved, occurred in Norway between December 2012 and
August 2013. In the first case of the three, AH-7921 was not
analytically confirmed in biological samples, but its use was
suspected due to the detection of AH-7921 in the small
amounts of a white powder found in a bag and in a syringe
with dried blood at the location close to the deceased during
the investigation at the scene of death. Etizolam and phena-
zepam were also found in the bag and the syringe. In the
second case, a 23-year-old male probably bought drugs via
the Internet and overdosed. AH-7921 was detected in his
peripheral blood at a concentration of 0.428 lg/ml. 2-Fluor-
omethamphetamine, 3-methylmethcathinone, codeine, and
paracetamol were also detected. In the third case, the death
was associated with AH-7921 in Norway, but the drug was
analyzed in Sweden. AH-7921 was quantified in femoral
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blood at a concentration of 0.34 lg/ml. Etizolam was also
detected [6, 14, 15].
Three deaths associated with AH-7921 were also
reported in the United Kingdom between February 2013
and August 2013. The involvement of this NPS was ana-
lytically confirmed [25]. In the first case (February 2013),
AH-7921 was detected in postmortem femoral blood at a
concentration of 0.58 lg/ml. In addition to AH-7921, eti-
zolam, etaqualone, mephedrone, pentedone, diphenylpro-
pinol, and 4-methylmethcathinone were detected in
postmortem urine. AH-7921 was also detected in a packet
of labeled powder found at the scene of death. In the
second case (July 2013), AH-7921 was determined at a
concentration of 0.05 lg/ml in the femoral blood of a man
found dead with a bag containing chloroform over his head.
Chloroform and ethanol were also detected from his blood.
In August 2013, the victim of the third case was found
unresponsive at home and died later after being transferred
to a hospital. In postmortem femoral blood, AH-7921
(4.46 lg/ml), mirtazapine, and doxylamine were detected.
Their presence was also confirmed in urine along with
clobazam and a codeine metabolite [6, 14, 15].
Ten lethal cases were reported in Sweden between
January and September 2013, and all cases were analyti-
cally confirmed. In nine of them, AH-7921 was determined
in femoral blood at concentrations ranging from 0.03
to 0.99 lg/ml, while in the tenth case it was detected
postmortem in hair although not quantified. In all cases, at
least one other psychoactive substance was detected during
the toxicological analysis. These substances included
amphetamine (two cases), 3-methylmethcathinone (two
cases), a metabolite of ketamine, alcohol, buprenorphine,
and drugs such as benzodiazepines (alprazolam, diazepam,
nordazepam, pyrazolam), pregabalin, gabapentin, zopi-
clone, mirtazapine, paroxetine, bupropion, and aripipra-
zole. In three cases, the death was attributed to ‘‘toxic
effect of AH-7921’’ or ‘‘overdose of AH-7921’’, while in
four cases, the causes of death were given as ‘‘unintentional
overdose’’, ‘‘overdose of benzodiazepines and opiates’’,
‘‘intoxication with opioids among others’’, and ‘‘pneumo-
nia caused by aspiration’’. In two cases, the cause of death
was reported as ‘‘unclear’’, and in the last case, no further
information was provided [6, 9, 14, 15].
Vorce et al. [26] reported a death in the USA associated
with AH-7921 of a 19-year-old male found dead in bed by
his friend. The latter indicated that the deceased had pur-
chased two vials of an unknown drug and used them for
two consecutive nights. He died during the second night.
Pulmonary congestion, edema of the lungs, and enlarge-
ment of the liver and spleen were revealed during autopsy.
The analysis of the content of the two vials found at the
scene identified AH-7921 in one vial and 4-methyl-a-pyr-
rolidinohexanophenone (MPHP) in another vial. In the
postmortem blood, only AH-7921 was detected and quan-
tified, while dextromethorphan and MPHP were found in
the postmortem urine along with AH-7921. The death was
attributed to AH-7921 intoxication. The drug was
obviously taken at the night of his death.
Analysis of AH-7921 in seized materials and biological
samples
Because of the chemically basic nature and structure of
AH-7921, its extraction from biological samples and ana-
lysis are simple, easy, and thus amenable to a number of
techniques.
Soh and Elliot [27] reported the development of high-
performance liquid chromatography–diode array
(HPLC–DAD) detection, liquid chromatography–tandem
mass spectrometry (LC–MS-MS), and ultra high-per-
formance liquid chromatography–quadrupole time-of-
flight-mass spectrometry methods for determination of
AH-7921 and its metabolites simultaneously with other
NPSs and their metabolites in blood and plasma
samples. AH-7921 was liquid–liquid extracted with
1-chlorobutane after alkalization of the biological sam-
ples. The developed methods were applied for forensic
purposes and were also used to study the stability of
these emerging substances and their metabolites in the
biological fluids [27].
Uchiyama et al. [11] detected and identified AH-7921 in
an illegal product in Japan based on previously published
gas chromatography–mass spectrometry (GC–MS) and
ultra performance liquid chromatography–electronspray
ionization–mass spectrometry techniques after extraction
with methanol from herbal-type products crushed to pow-
der [28].
Vorce et al. [26] developed an analytical method using
GC–MS for detection and quantification of AH-7921 dur-
ing toxicological analysis of biological samples. The iso-
lation of AH-7921 from postmortem blood was succeeded
by liquid–liquid extraction with n-butyl chloride from
alkalinized samples. The analyses were based on the use of
GC–MS using selected ion monitoring mode; the electron
impact (EI) mass spectrum of the underivatized AH-7921
showed characteristic fragments at m/z 126 (base peak),
145, and 173. Two other substances were also detected.
Their characteristic fragments were m/z 112 (base peak),
145, and 173, and m/z 98 (base peak), 145, 173, respec-
tively. They were suggested to be the AH-7921 metabo-
lites, N-desmethyl-AH-7921 and N,N-didesmethyl-AH-
7921, produced by the demethylation and di-demethylation
of the N,N-dimethylcyclohexanamine group, respectively
[26]. However, the absence of metabolic studies and cer-
tified reference standards precluded the verification of the
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other detected substances as metabolites. The possibility
also exists that these substances could be contaminants or
byproducts found in the material.
Nuclear magnetic resonance and Fourier transform in-
frared spectra of AH-7921 are available at European in-
formation system and database on new drugs and could be
used for the identification of the drug in seized materials
[10, 29–31].
Legal status
AH-7921 is currently controlled in six European countries
(Sweden, Poland, Romania, Finland, Netherlands, and
Norway) [6]. Particularly, in Sweden it is controlled under
the Narcotic Drugs Control Act (SFS 1992-860) and the
Narcotic Drugs Control Ordinance (SFS 1994-1554) com-
plying with the obligations of the 1971 United Nations
Convention on Psychotropic Substances. In Poland, AH-
7921 fell under the definition of a ‘‘substitution’’ drug
under the act amending the Act on State Sanitary Inspec-
tion (2010), and thus its production and marketing are
penalized with administrative sanctions (i.e. fine). In
Romania it is controlled under Law 194/2011 as a sub-
stance with psychoactive potential until proven harmless.
Netherlands and Finland reported that AH-7921 is a con-
trolled substance and must comply with medicine legisla-
tion (in Finland since 15 March 2013—Medicines Act
395/87). In Norway it is regulated by the Medicines Act,
and is available only by prescription. There is no infor-
mation regarding the control status of AH-7921 in Spain.
The remaining 22 Member States (Austria, Belgium, Bul-
garia, Croatia, Cyprus, the Czech Republic, Denmark,
Estonia, France, Germany, Greece, Hungary, Ireland, Italy,
Latvia, Lithuania, Luxembourg, Malta, Portugal, Slovakia,
Slovenia, and the United Kingdom) and Turkey reported
that AH-7921 is not controlled at the national level,
although Germany intended to introduce national measures
for this NPS [6, 14, 15, 29, 32]. In June 2014, the European
Commission proposed to member states to take the nec-
essary measures to subject AH-7921, along with other
NPSs, to control to prevent its further spread [32]. Fol-
lowing this proposal, a decision on scheduling AH-7921 in
the member states was taken in September 2014 [6]. The
distribution of AH-7921 has been considered to be illegal
in Israel since 12 September 2013 [33]. In Australia, AH-
7921 was scheduled as a Prohibited Substance (subjected to
Schedule 9 of the Standard for the Uniform Scheduling of
Medicines and Poisons) in May 2014, although this
amendment has been repealed as of 2 June 2014 [34]; but
its import is still banned. It is expected that AH-7921 will
be a controlled substance in most countries worldwide by
the end of 2015.
Conclusions
AH-7921 is an NPS available online and constitutes a
public health danger in many countries worldwide. It is a
potential analgesic drug with addictive properties and has
been synthesized to mimic the effects of morphine, fen-
tanyl, and phencyclidine due to structural similarity to the
latter two, and at the same time, it outsmarts the drug
laws. AH-7921 was first synthesized in the mid-1970s, but
it only recently (in 2012) appeared on the drug market
and gained the attention of authorities due to the in-
toxications and fatalities it caused. It is considered a
synthetic opioid, and its pharmacological properties are
similar to morphine. Potential side effects include miosis,
hypothermia, sedation, respiratory depression, and inhi-
bition of gastrointestinal propulsion, as well as, in severe
cases, death. The drug is available online in the powder
form, and is often used concomitantly with other recre-
ational drugs. In 2012 and 2013, a number of reported
deaths associated with the intake of AH-7921 led to
control of this substance in six European countries, Israel,
and Australia. In September 2014, the European Com-
mission published a decision calling upon its member
states to take the necessary measures to subject AH-7921,
along with other NPSs, to control to prevent its further
spread. Similar actions are expected to be taken
worldwide.
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